The results suggest that combination therapy of a chemotherapeutic agent with erlotinib showed stronger antitumor effect compared with chemomonotherapy against erlotinib-resistant tumors in that erlotinib inhibited the phosphorylation of EGFR in the tumor. Here, EGFR is linked to neoplasm.